Amedisys Releases Report from Marwood Group Advisory

BATON ROUGE, La.--(Business Wire)--
Amedisys, Inc. (NASDAQ: AMED)(the "Company"), one of America's leading home
health and hospice nursing companies, today released the results of a review
conducted by Marwood Group Advisory, LLC (Marwood). Several months ago Amedisys
engaged Marwood, one of the nation`s preeminent health care consulting firms, to
provide an independent analysis of the Company`s procedures, controls, clinical
infrastructure, corporate compliance processes, technology offerings and future
strategies. Marwood conducted a review of academic research, over 11,000 pages
of Company specific documents, interviews with 18 members of Company leadership,
and interviews with a cross section of other home health providers from across
the nation, and utilized its home health industry, legislative and regulatory
knowledge to measure industry standards, best practices and leading practices to
evaluate the Amedisys model and infrastructure. The results showed that Amedisys
ranked highest compared to other publicly traded home health companies in terms
of quality improvement and compliance processes. Among their findings, Marwood
stated, "Amedisys also employs best practices in the areas of field clinician
coding and accuracy, oversight and management infrastructure, corporate
compliance, and care coordination technology." They further state, "Based on our
Quality and Compliance Process Scorecard and information collected during our
review of Company documentation and onsite interviews, Marwood believes that,
overall, Amedisys has implemented compliance and quality improvement processes
that meet and/or exceed the industry average."

The entire report has been posted to our website at www.amedisys.com.

"We are pleased with the results that Marwood found in their review of our
Company," stated William F. Borne, Chief Executive Officer. "We operate our
Company with a view toward providing clinical excellence for our patients while
maintaining effective compliance and controls, and these findings evidence our
leadership in these and other measures."

Marwood Group Advisory, LLC and its affiliated companies (Member FINRA and SIPC)
is a nationally recognized healthcare advisory and financial services firm
headquartered in New York City with additional offices in Washington DC and
London. Marwood has over 90 employees including former senior White House staff,
federal agency leaders (including CMS, FDA, HHS and AHRQ) and congressional
committee staff members as well as former senior healthcare operators from
health plans and hospitals, former employees of state agencies, and former
management consultants who monitor and analyze issues related to healthcare.
Marwood provides specialized analysis for corporations, financial sponsors and
other investors looking to evaluate the regulatory and reimbursement framework
and risks associated with making direct investments in healthcare services, life
sciences, and devices.

Amedisys, Inc. is headquartered in Baton Rouge, Louisiana. Its common stock
trades on the NASDAQ Global Select Market under the symbol "AMED."

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe", "estimate", "project",
"expect", "anticipate" or similar expressions.Forward-looking statements
inherently involve risks and uncertainties that could cause actual results to
differ materially from the forward-looking statements.Many of the factors that
could cause or contribute to such differences are described in the Company`s
periodic reports and registrations statements filed with the Securities and
Exchange Commission, and include, but are not limited to the following: general
economic and business conditions, changes in or failure to comply with existing
regulations or the inability to comply with new government regulations on a
timely basis, changes in Medicare and other medical reimbursement levels,
ability to complete acquisitions announced from time to time, and any financing
related thereto, the ability to meet debt service requirements and to comply
with covenants in debt agreements, adverse changes in federal and state laws
relating to the health care industry, demographic changes, availability and
terms of capital, ability to attract and retain qualified personnel, ongoing
development and success of new start-ups, ability to successfully integrate
newly acquired agencies, changes in estimates and judgments associated with
critical accounting policies, business disruption due to natural disasters or
acts of terrorism, and various other matters, many of which are beyond
management`s control. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or changes
after the date of this release.

Our company website address is www.amedisys.com. We use our website as a channel
of distribution for important company information. Important information,
including press releases, analyst presentations and financial information
regarding the Company is routinely posted on and accessible on the "Investor
Relations" subpage of our website, which is accessible by clicking on the tab
labeled "Investors" on our website home page.We will also use our website to
expedite public access to time-critical information regarding the Company in
advance of or in lieu of distributing a press release or a filing with the
Securities and Exchange Commission ("SEC") disclosing the same information.In
addition, we make available on the Investor Relations subpage of our website
(under the link "SEC filings") free of charge our annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports
on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable
after we electronically file such reports with the SEC. Further, copies of our
Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct
and the charters for the Audit, Compensation and Nominating and Governance
Committees of our Board are also available on the Investor Relations subpage of
our website (under the link "Corporate Governance").

Additional information on the Company can be found at:
www.amedisys.com

Amedisys, Inc.
Kevin B. LeBlanc, 225-292-2031
Director of Investor Relations
kleblanc@amedisys.com

Copyright Business Wire 2009